-Series A Financing Provided by Samsara BioCapital, Red Tree Venture Capital, and Decheng Capital -
-Industry Veteran Todd Zavodnick Appointed President and CEO to Lead Experienced Clinical Development Team -
PALO ALTO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a new class of allergy therapeutics, today announced its launch with a $70 million Series A financing to advance its pipeline of first-in-class allergic Effector Cell Response Inhibitors (ECRIs).
Seeded in 2021 by Red Tree Venture Capital and headquartered in Palo Alto, California, Excellergy is trailblazing a new therapeutic category designed to deliver complete control of allergic disease. Building on scientific advances into the structural binding of IgE to its receptor from Stanford University and the University of Bern, the company has developed a portfolio of trifunctional ECRIs that leverage well-established IgE pharmacology while moving beyond its current limits, with the goal of redefining the standard of care in multiple allergic diseases.
This new class of ECRIs employs a trifunctional mechanism of action to: (1) rapidly remove IgE bound to FceRI on mast cells and basophils without triggering activation of these cells; (2) deliver potent, high-affinity neutralization of free IgE; and (3) accelerate downregulation of FceRI expression. Acting synchronously, these three functions have the potential to enable faster onset and more complete ...
